

<b>National Imaging Associates, Inc.*</b>	
<b>Clinical guidelines:</b> <b>PROTON BEAM RADIATION THERAPY</b>	<b>Original Date: June 2013</b>
<b>CPT codes: 77520,77522,77523,77525</b>	<b>Last Revised Date: February 2021</b>
<b>Guideline Number: NIA_CG_221</b>	<b>Implementation Date: January 2022</b>

Most requests for radiation therapy are addressed by NIA treatment site clinical guidelines. However, there may be requests that are not. For such requests, determinations will be made on a case-by-case basis utilizing the following guidelines (when applicable) but not limited to: National Comprehensive Cancer Network (NCCN), American Society for Radiation Oncology ASTRO (i.e., Model Policies; Evidence-Based Consensus Statement), ACR Appropriateness Criteria, American Society of Clinical Oncology (ASCO) and/or peer reviewed literature.

### **MEDICALLY NECESSARY INDICATIONS FOR PROTON BEAM THERAPY (Requires Physician Review)**

#### **Treatment of the following in children less than 21 years of age**

- Primary or benign solid tumors (curative intent; occasional palliative treatment) when sparing of surrounding normal tissues cannot be achieved with photon therapy

#### **Treatment at any age (ASTRO, 2017)**

- Primary hepatocellular tumors treated with hypofractionated regimens
- Spinal tumors (primary or metastatic) where spinal cord has previously been treated with radiation or where the spinal cord tolerance may be exceeded with conventional treatment
- Tumors at the base of skull (chordoma, chondrosarcomas)
- Intraocular melanomas or other ocular tumors
- Patients with genetic syndromes making total volume of radiation minimization crucial, such as, but not limited to NF-1 patients and retinoblastoma patients
- Non-metastatic retroperitoneal sarcomas
- Re-irradiation cases (where cumulative critical structure dose would exceed tolerance dose)

### **OTHER TREATMENT OPTIONS REQUIRING PHYSICIAN REVIEW (ASTRO, 2017; NCCN, 2019)**

For peer review purposes supporting documentation from the radiation oncologist is required and should include the clinical rationale for performing proton beam rather than 3-D conformal or IMRT or SRS.

---

\* National Imaging Associates, Inc. (NIA) is a subsidiary of Magellan Healthcare, Inc.

Proton beam therapy has not been proven to be superior to conventional radiation therapy for all other indications including, but not limited to:

- Prostate cancer
- Breast cancer
- Lung cancer
- Colorectal cancer
- Cervical cancer
- Metastasis
- Gliomas
- Soft tissue sarcoma
- Head and Neck
- Pelvic
- Gastric

---

---

## BACKGROUND

Proton beam therapy (PBT) is a type of external beam radiotherapy that uses charged particles. These particles have unique characteristics including limited lateral spread, scatter, and tissue in a defined range, going for maximum dose delivery over the last few millimeters of the particles' range. The maximum is called the Bragg peak. Proton beam irradiation when applied to treating cancer, uses different proton energy with Bragg peaks at various steps, enabling dose escalation to the tumor, minimizing excess dose to normal surrounding tissue. Over the years, proton beam irradiation has been applied to treating tumors that require dose escalation to achieve a higher probability of cure, as well as tumors requiring increased precision in dose deposition while protecting normal surrounding tissue. Proton therapy has an over 40-year history in treating cancer, yet to date, there have been few studies that show superiority to conventional photon beam irradiation, especially with modern techniques.

## POLICY HISTORY

Date	Summary
February 2021	No Changes
February 2020	Added and updated references
February 2019	Added and updated references

## REFERENCES

- Al-Shahi R, Warlow CP. Interventions for treating brain arteriovenous malformations in adults. *Cochrane Database Syst Rev.* 2006; (1): CD003436.
- Allen A, Pawlicki T, Bonilla L, et al. Evaluation Subcommittee of ASTRO's Emerging Technologies Committee (ETC). An evaluation of proton beam therapy. Fairfax, VA: American Society for Radiation Oncology (ASTRO); October 2009.
- Allen AM, Pawlicki T, Dong L, et al. An evidence based review of proton beam therapy: The report of ASTRO's emerging technology committee. *Radiother Oncol.* April 2012; 103(1):8-11.
- Almefty K, Pravdenkova S, Colli BO, et al. Chordoma and chondrosarcoma: Similar, but quite different, skull base tumors. *Cancer.* 2007; 110(11):2457-2467.
- American College of Radiology (ACR). ACR-ASTRO Practice Parameter for the Performance of Proton Beam Radiotherapy. Amended 2014.  
[https://www.acr.org/~media/ACR/Documents/PCTS/guidelines/Rad\\_Onc\\_Proton\\_Therapy.pdf](https://www.acr.org/~media/ACR/Documents/PCTS/guidelines/Rad_Onc_Proton_Therapy.pdf). Accessed May 15, 2017.
- American Society for Radiation Oncology (ASTRO). Model Policies. Proton Beam Therapy (PBT).  
[https://www.astro.org/uploadedFiles/\\_MAIN\\_SITE/Daily\\_Practice/Reimbursement/Model\\_Policies/Content\\_Pieces/ASTROPBTModelPolicy.pdf](https://www.astro.org/uploadedFiles/_MAIN_SITE/Daily_Practice/Reimbursement/Model_Policies/Content_Pieces/ASTROPBTModelPolicy.pdf). June 2017. Accessed May 3, 2018.
- American Society for Radiation Oncology (ASTRO). Ten Things Physicians and Patients Should Question. Keyword: Proton. Choosing Wisely®. <http://www.choosingwisely.org/societies/american-society-for-radiation-oncology/>. Released September 23, 2013. Accessed May 3, 2018.
- Bassim MK, Berliner KI, Fisher LM, et al. Radiation therapy for the treatment of vestibular schwannoma: A critical evaluation of the state of the literature. *Otol Neurotol.* 2010; 31(4):567-573.
- Bekkering GE, Rutjes AW, Vlassov VV, et al. The effectiveness and safety of proton radiation therapy for indications of the eye: A systematic review. *Strahlenther Onkol.* April 2009; 185(4):211-221.
- Bentzen SM, Constine LS, Deasy JO, et al. Quantitative analyses of normal tissue effects in the clinic QUANTEC: An introduction to the scientific issues. Introductory paper. *Int J Radiat Oncol Biol Phys.* 2010; 76(3):S3-S9.
- Brada M, Pijls-Johannesma M, De Ruyscher D. Current clinical evidence for proton therapy. *Cancer J.* July/August 2009; 15(4):319-324.
- Bush DA, Kayali Z, Grove R, et al. The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: A phase 2 prospective trial. *Cancer.* July 1, 2011; 117(13):3053-3059.

Bush DA, Slater JD, Garberoglio C, et al. A technique of partial breast irradiation utilizing proton beam radiotherapy: Comparison with conformal x-ray therapy. *Cancer J*. 2007; 13(2):114-118.

Chan RV, Yonekawa Y, Lane AM, et al. Proton beam irradiation using a light-field technique for the treatment of choroidal hemangiomas. *Ophthalmologica*. 2010; 224(4):209-16.

Chang JY, Komaki R, Lu C, et al. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. [Published online ahead of print March 22, 2011]. *Cancer*. October 15, 2011; 117(20):4707-4713.

Chung CS, Yock TI, Nelson K, et al. Incidence of second malignancies among patients treated with proton versus photon radiation. *Int J Radiat Oncol Biol Phys*. 2013 Sep 1; 87(1):46-52. [http://www.redjournal.org/article/S0360-3016\(13\)00459-8/abstract](http://www.redjournal.org/article/S0360-3016(13)00459-8/abstract).

Coen JJ, Zietman AL. Proton radiation for localized prostate cancer. *Nat Rev Urol*. 2009; 6(6):324-330.

Efstathiou JA, Trofimov AV, Zietman AL. Life, liberty, and the pursuit of protons: An evidence-based review of the role of particle therapy in the treatment of prostate cancer. *Cancer J*. 2009; 15(4):312-318.

Fitzek MM, Linggood RM, Adams J, et al. Combined proton and photon irradiation for craniopharyngioma: Long-term results of the early cohort of patients treated at Harvard Cyclotron Laboratory and Massachusetts General Hospital. *Int J Radiat Oncol Biol Phys*. 2006; 64(5):1348-1354.

Flynn K. Brief overview: Reviews of proton beam therapy for cancer. Boston, MA: Veterans Health Administration Technology Assessment Program (VATAP); August 2007.

Grutters JP, Kessels AG, Pijls-Johannesma M, et al. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: A meta-analysis. *Radiother Oncol*. April 2010; 95(1):32-40.

Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. *Int J Radiat Oncol Biol Phys*. 2006; 65(1):1-7.

Hata M, Tokuyue K, Kagei K, et al. Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: Preliminary results of a phase I/II clinical study. *Int J Radiat Oncol Biol Phys*. 2007; 68(3):786-793.

Hocht S, Wachtlin J, Bechrakis NE, et al. Proton or photon irradiation for hemangiomas of the choroid? A retrospective comparison. *Int J Radiat Oncol Biol Phys*. October 1, 2006; 66(2):345-51.

Hong TS, Ryan DP, Blaszkowsky LS, et al. Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the head. *Int J Radiat Oncol Biol Phys*. 2011; 79(1):151-157.

Institute for Clinical and Economic Review (ICER). Brachytherapy and proton beam therapy for treatment of clinically localized, low-risk prostate cancer. Final Appraisal Document. Boston, MA: ICER; December 22, 2008.

Jackson A, Marks LB, Bentzen SM, et al. The lessons of QUANTEC: Recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome. *Int J Radiat Oncol Biol Phys*. 2010; 76(3):S155-S160.

Kavanagh BD, Pan CC, Dawson LA, et al. Radiation dose-volume effects in the stomach and small bowel. QUANTEC: organ-specific paper. *Int J Radiat Oncol Biol Phys*. 2010; 76(3 Suppl):S101-S107.

Kirkpatrick JP, Van Der Kogel AJ, Schultheiss TE. Radiation dose-volume effects in the spinal cord. QUANTEC organ-specific paper. *Int J Radiat Oncol Biol Phys*. 2010; 76(3):S42-S49.

Konski A, Speier W, Hanlon A, et al. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? *J Clin Oncol*. 2007a; 25:3565-3566.

Konski A, Speier W, Hanlon A, et al. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? *J Clin Oncol*. 2007b; 25(24):3603-3608.

Kozak KR, Smith BL, Adams J, et al. Accelerated partial-breast irradiation using proton beams: Initial clinical experience. *Int J Radiat Oncol Biol Phys*. 2006; 66(3):691-698.

Levy-Gabriel C, Rouic LL, Plancher C, et al. Long-term results of low-dose proton beam therapy for circumscribed choroidal hemangiomas. *Retina*. February 2009; 29(2):170-175.

Lodge M, Pijls-Johannesma M, Stirk L, et al. A systematic literature review of the clinical and cost-effectiveness of hadron therapy in cancer. *Radiother Oncol*. 2007; 83(2):110-122.

Macdonald OK, Kruse JJ, Miller JM, et al. Proton beam radiotherapy versus three-dimensional conformal stereotactic body radiotherapy in primary peripheral, early-stage non-small-cell lung carcinoma: A comparative dosimetric analysis. *Int J Radiat Oncol Biol Phys*. 2009; 75(3):950-958.

Marks LB, Bentzen SM, Deasy JO, et al. Radiation dose-volume effects in the lung. QUANTEC: Organ specific paper. *Int J Radiat Oncol Biol Phys*. 2010; 76(3):S70-S76.

Merchant TE. Proton beam therapy in pediatric oncology. *Cancer J*. 2009; 15(4):298-305.

Mizumoto M, Sugahara S, Nakayama H, et al. Clinical results of proton-beam therapy for locoregionally advanced esophageal cancer. *Strahlenther Onkol*. 2010; 186(9):482-488.

National Comprehensive Cancer Network (NCCN). NCCN guidelines and clinical resources. 2019. [https://www.nccn.org/professionals/physician\\_gls/default.aspx#site](https://www.nccn.org/professionals/physician_gls/default.aspx#site).

National Guideline Clearinghouse (NGC). Guideline summary: Proton beam radiation therapy. In: National Guideline Clearinghouse (NGC) [Web site]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 2013 Mar 01.

Nguyen PL, Trofimov A, Zietman AL, et al. Proton-beam vs intensity-modulated radiation therapy. Which is best for treating prostate cancer? *Oncology (Williston Park)*. June 2008; 22(7):748-754; discussion 754, 757.

Nihei K, Ogino T, Ishikura S, et al. High-dose proton beam therapy for Stage I non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys*. 2006; 65(1):107-111.

Nishimura H, Ogino T, Kawashima M, et al. Proton-beam therapy for olfactory neuroblastoma. *Int J Radiat Oncol Biol Phys*. 2007; 68(3):758-762.

Ollendorf DA, Hayes J, McMahon P, et al. Brachytherapy/proton beam therapy for clinically localized, low-risk prostate cancer. Boston, MA: Institute for Clinical and Economic Review (ICER); 2008.

Olsen DR, Bruland OS, Frykholm G, et al. Proton therapy - a systematic review of clinical effectiveness. *Radiother Oncol*. May 2007; 83(2):123-32.

Pijls-Johannesma M, Grutters JP, Verhaegen F, et al. Do we have enough evidence to implement particle therapy as standard treatment in lung cancer? A systematic literature review. *Oncologist*. 2010; 15(1):93-103.

Ramaekers BL, Pijls-Johannesma M, Joore MA, et al. Systematic review and meta-analysis of radiotherapy in various head and neck cancers: comparing photons, carbon-ions and protons. *Cancer Treat Rev*. May 2011; 37(3):185-201.

Schulz RJ, Kagan AR. Should proton-beam therapy be widely adopted? *Int J Radiat Oncol Biol Phys*. 2008; 72(5):1307-1310. Sejpal S, Komaki R, Tsao A, et al. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for non-small cell lung cancer. *Cancer*. July 1, 2011; 117(13):3004-3013.

Sheets NC, Goldin GH, Meyer AM, et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. *JAMA*. Apr 18, 2012; 307(15):1611-1620.

Terasawa T, Dvorak T, Ip S, et al. Systematic review: Charged-particle radiation therapy for cancer. *Ann Intern Med*. 2009; 151(8):556-565.

Trikalinos TA, Terasawa T, Ip S, et al. Particle Beam Radiation Therapies for Cancer. Technical Brief No. 1. (Prepared by Tufts Medical Center Evidence-based Practice Center under Contract No. HHS-290-07-10055). Rockville, MD: Agency for Healthcare Research and Quality (AHRQ).

Van de Water TA, Bijl HP, Schilstra C, et al. The potential benefit of radiotherapy with protons in head and neck cancer with respect to normal tissue sparing: A systematic review of literature. *Oncologist*. 2011; 16(3):366-377.

Vargas C, Fryer A, Mahajan C, et al. Dose-volume comparison of proton therapy and intensity modulated radiotherapy for prostate cancer. [Published online ahead of print September 27, 2007]. *Int J Radiat Oncol Biol Phys*. March 1, 2008; 70(3):744-751.

Widesott L, Amichetti M, Schwarz M. Proton therapy in lung cancer: clinical outcomes and technical issues. A systematic review. *Radiother Oncol*. February 2008; 86(2):154-164.

Wilt TJ, MacDonald R, Rutks I, et al. Systematic review: Comparative effectiveness of therapies for clinically localized prostate cancer. *Ann Intern Med*. 2008a; 148:435-448.

Wilt TJ, Shamliyan T, Taylor B, et al. Comparative effectiveness of therapies for clinically localized prostate cancer. Comparative Effectiveness Review No. 13. Rockville, MD: Agency for Healthcare Research and Quality (AHRQ); 2008b.

Zambarakji HJ, Lane AM, Ezra E, et al. Proton beam irradiation for neovascular age-related macular degeneration. *Ophthalmology*. 2006; 113(11):2012-2019.

Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: Long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. *J Clin Oncol*. March 1, 2010; 28(7):1106-1111.

Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. *JAMA*. 2005; 294(10):1233-1239.

**Reviewed / Approved by NIA Clinical Guideline Committee**

## GENERAL INFORMATION

It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. If applicable: All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.

**Disclaimer:** Magellan Healthcare service authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Magellan Healthcare subsidiaries including, but not limited to, National Imaging Associates (“Magellan”). The policies constitute only the reimbursement and coverage guidelines of Magellan. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. Magellan reserves the right to review and update the guidelines at its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.